Knight Therapeutics Inc T.GUD

Alternate Symbol(s): KHTRF

Healthcare

Knight Therapeutics Inc. is a specialty pharmaceutical company. The Company’s principal business activity is developing, acquiring, in-licensing, out-licensing, manufacturing, marketing and distributing pharmaceutical products in Canada, Latin America and select international markets. It finances other life sciences companies and secures product distribution rights for Canada and select international markets. The Company invests in life sciences venture capital funds whereby the Company may receive preferential access to healthcare products for Canada and select international markets. It develops pharmaceutical products, including those to treat neglected tropical and rare pediatric diseases. The portfolio consists of pharmaceutical products with molecules and includes both in-licensed products such as Lenvima, Cresemba, Halaven, Trelstar, Akynzeo, Ambisome, Minjuvi, Imvexxy as well as products owned by Knight such as Exelon and Impavido.

TSX:GUD - Post by User

Knight Therapeutics Inc > Expectations

<< Previous

Bullboard Posts

Next >>

Comment by MrMugsyon Aug 07, 2022 11:56am

166 Views

Post# 34877148

RE:Expectations

Haven't been paying attention to this lately but - investment in Singlar G also took another hit as the stock likely bottomed in the last quarter and we will probably take an adjustment hit. Highly doubt there were any investment wins in the last quarter as the general markets were rocked.

Might just be the end of that Genome saga as Revenues slowly mute out that noise.

IMO.

<< Previous

Bullboard Posts

Next >>

Paramount Resources signs $3.32 billion asset sale